Tuesday, November 4, 2014

Medscape - What's Hot at the Liver Meeting 2014


What's Hot at the Liver Meeting 2014
Neil Osterweil
November 04, 2014

BOSTON — The 2014 Liver Meeting returns to Boston, home of splendors such as beans, cod, the Boston Red Sox, world-class medical centers, and pharmaceutical research hubs.

The meeting, during which the American Association for the Study of Liver Diseases (AASLD) struts it stuff each year, will be held at the John B. Hynes Veterans Memorial Convention Center from November 7 to 11.

The Hynes, sandwiched between Boylston Street — the city's liveliest thoroughfare — and the hotels, shops, and restaurants of the Prudential Center complex, has hosted many previous Liver Meetings, and is ideally located to take advantage of the wealth of science the conference provides and all of the amenities that Boston has to offer.

Nearly 3000 abstracts were submitted by clinicians and scientists for this year's event, covering the latest clinical trial results, practice-changing clinical findings, and basic research into the mechanisms and molecular targets of diseases of the liver.

"We're going to hear a lot about fatty liver disease; the number of abstracts about fatty liver disease this year just exploded, as did the number of abstracts about complications of cirrhosis," Gary Davis, MD, AASLD secretary, told Medscape Medical News.

"This reflects what people are seeing in the clinic. The buzz for hepatitis C has died down a bit, I think because the treatment is so effective now and it's so easy to administer," he said.

Cutting Edge

That the care of patients with hepatitis C would become almost routine — or indeed that such an entity as hepatitis C ever existed — would have seemed like wild fantasy 40 years ago.

But that's just what attendees can expect to hear during the President's Choice Lecture from Willis Maddrey, MD, from the University of Texas Southwestern Medical Center at Dallas.

"Dr Maddrey is always a pretty dynamic speaker," Dr Davis said.

He pointed out that Dr Maddrey has witnessed the advent of genetic research into fatty liver disease, pegylated interferons, protease inhibitors, and other discoveries in his more than 40 years in the trenches.

Of course, with the advent of effective combination therapies for hepatitis C comes the inevitable increase in costs, just as pressures for accountability and value in medical care rise.

"There will be some presentations on cost-effectiveness, but surprisingly not a lot, given all the press it has gotten over the past year, but I want to be in the room for those. I think the discussions after the abstracts are presented will be pretty good," Dr Davis said.

On a related theme, new this year will be a symposium on value-based medicine in hepatology. The session will focus on coping in the era of Accountable Care Organizations and the Affordable Care Act. Or as the Liver Meeting program describes it, "the concept of value-based medicine and the importance of returning the practice of hepatology to its appropriate focus: enabling the health and effective care of patients with liver disease."

The $1000-per-dose therapies for hepatitis C viral infections are a challenge in this era.

The Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture, by Jean Edmond, MD, from New York Presbyterian Hospital and Columbia Medical Center in New York City, will focus on the controversial topic of living-donor transplantation. Dr Edmond will outline patient and donor selection and describe the most up-to-date methods of harvesting and transplantation.

The Emerging Trends Symposium, which will follow Dr Edmond's talk, will center on a topic that might be new to some conference goers: acute on chronic liver failure. The condition is defined as acute decompensation of a patient with cirrhosis and characterized by multiple organ failure. Attendees will learn about the pathophysiology of acute liver failure, clinical issues associated with the syndrome, and investigational therapies.

The Hans Popper Basic Science State-of the-Art Lecture will be devoted to induced pluripotent stem cells and their use in the study of liver disease and development. Stephen Duncan, DPhil, from the Medical College of Wisconsin in Milwaukee, is expected to describe his groundbreaking work coaxing stem cells to differentiate into hepatocytes, Dr Davis said.

Abstract Sessions and Late-Breakers

The scientific sessions kick off on Saturday, November 8, with the first of four poster sessions covering more than 2000 research projects, from basic science findings to the latest in clinical practice, drug development, and clinical trials.

Sunday will feature transplant plenary sessions, Monday basic science and clinical plenary, and Tuesday the hepatitis plenary.

Late-breaking oral abstracts will be presented on Monday afternoon, and late-breaking posters will be on view all day Monday, with presenters available from 12:30 to 3:00 pm.

This year's late-breakers will include:
  • Results of the STOPAH trial comparing steroids with pentoxifylline for alcoholic hepatitis
  • Phase 3 results from the UNITY-2 trial of an oral fixed-dose combination therapy for patients with chronic hepatitis C genotype 1 infections and compensated cirrhosis
  • Results of the phase 3 ALLY-3 study looking at an oral ribavirin-free combination for the treatment of hepatitis C genotype 3
  • A study of post-transplant direct-acting antiviral agents for hepatitis C
  • Results from a phase 3 randomized controlled trial of an enzyme replacement therapy in children and adults with lysosomal acid lipase deficiency
  • A report on a phase 2a proof-of-concept trial of a hepatitis B and hepatitis D entry inhibitor
Ticketed educational sessions will run the gamut, from endoscopy, transplantation, pediatric hepatology, and basic research, to practical matters such as competency training and career development.

As you can still hear in some of Boston's more traditional neighborhoods, this year's Liver Meeting promises to be "wicked good."

Dr Davis have disclosed no relevant financial relationships.
Medscape Medical News > Conference News

Free Access: Overcoming the roadblocks in HCV, Facts and fictions of HCV and comorbidities and More....

Good morning folks, looking to catch up on some HCV reading? The Journal of Hepatology is open access this month, check out the highlights below, in addition download EASL Recommendations on Treatment of Hepatitis C 2014.

Journal of Hepatology

This state-of-the-art collection has been produced by leading experts in the field covering all the important aspects of hepatitis C.

Twenty-five years following the discovery of the hepatitis C virus, the Journal of Hepatology brings you a comprehensive overview of the milestones in basic science and clinical developments and highlights the remaining challenges in the prevention and treatment of HCV infection.
Editorial
Basic
Koen Vercauteren, Ype P. de Jong, Philip Meuleman
S26–S33
Thomas F. Baumert, Catherine Fauvelle, Diana Y. Chen, Georg M. Lauer
S34–S44
Clinical Course
Erin Gower, Chris Estes, Sarah Blach, Kathryn Razavi-Shearer, Homie Razavi
S45–S57
Published online: July 30, 2014
Rachel H. Westbrook, Geoffrey Dusheiko
S58–S68
Yujin Hoshida, Bryan C. Fuchs, Nabeel Bardeesy, Thomas F. Baumert, Raymond T. Chung
S79–S90
Treatment
Nathan Ford, Tracy Swan, Peter Beyer, Gottfried Hirnschall, Philippa Easterbrook, Stefan Wiktor
S132–S138



Achillion Reports Third Quarter and Nine Month 2014 Financial Results

Achillion Reports Third Quarter and Nine Month 2014 Financial Results

- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -

- Advancement of novel platform for complement factor D inhibitors for the oral treatment of immune-related rare diseases -

NEW HAVEN, Conn., Nov. 4, 2014
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2014, outlined upcoming milestones in its development programs for chronic hepatitis C viral infection (HCV), and introduced a novel platform for advancing oral complement factor D inhibitors.

For the third quarter of 2014, Achillion reported a net loss of $15.7 million or $0.16 per share, compared with a net loss of $13.9 million or $0.14 per share for the third quarter of 2013. Cash, cash equivalents, marketable securities, and interest receivable as of September 30, 2014 were $127.1 million.

Hepatitis C Development Program
During the remainder of 2014, Achillion expects to achieve the following milestones in its HCV development program:
  • Present Phase 2 SVR12 results following 8-weeks of treatment with the interferon-free, ribavirin-free regimen of ACH-3102, a second-generation NS5A inhibitor, and sofosbuvir in patients with treatment-naïve genotype 1 HCV. These results will be presented in a late breaker poster presentation and made available in a related press release along with development updates at The Liver Meeting 2014 (AASLD) which begins Saturday, November 8, 2014 in Boston, MA
     
  • Present three posters on ACH-3422, a uridine-analog nucleotide NS5B polymerase inhibitor prodrug, at AASLD that will detail the preclinical profile of this Phase 1 direct-acting antiviral agent for HCV; and
     
  • Report Phase 1 proof-of-concept results with ACH-3422 including safety following 14-day exposure in healthy volunteers and antiviral activity on treatment-naïve genotype 1 HCV patients.
"Over the course of 2014, we executed on our global HCV development plan and achieved several important milestones including the advancement of ACH-3422 into a Phase 1 trial, working with the FDA to remove the clinical hold on sovaprevir, our Phase 2 protease inhibitor, and continuing to demonstrate that, based upon results from three Phase 2 trials, ACH-3102 is a clearly differentiated NS5A inhibitor," commented David Apelian, M.D., Ph.D., Executive Vice President and Chief Medical Officer at Achillion. "As previously announced, we expect to report top-line results from our ongoing Phase 1 trial of ACH-3422 later this quarter and look forward to initiating a proprietary combination program evaluating ACH-3422, ACH-3102 and sovaprevir during 2015."

Complement Factor D Inhibitor Platform

Achillion also announced today that the Company has leveraged its internal discovery capabilities and a novel complement-related platform to develop oral inhibitors of complement factor D. Factor D is an essential serine protease involved in the complement pathway, a part of the innate immune system. The new complement platform is focused on advancing compounds that inhibit factor D, can be orally-administered, and potentially can be used in the treatment of immune-related diseases in which complement plays a critical role. Potential indications being evaluated for these compounds include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis, and age-related macular degeneration (AMD). Achillion anticipates that its platform could play a role to addressing the needs of all PNH patients, including patients who have suboptimal response to, or fail to respond to, the currently available treatment, as well as for patients suffering from other complement-mediated diseases.

Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion commented, "I am very proud of our accomplishments and we remain focused on transforming innovation into treatments that improve patients' lives. With our HCV compounds progressing through clinical development and on track to deliver additional results during the remainder of 2014, the Achillion discovery team has been focused on identifying and advancing exciting new candidates into our pipeline. We have now generated a portfolio of small molecule compounds that will be evaluated as orally administered inhibitors of complement factor D, potentially offering novel treatment options for patients with complement-related disease."

Can Exercise Help Patients with Cirrhosis?

Can Exercise Help Patients with Cirrhosis?

Eight weeks of aerobic exercise training increased peak oxygen uptake by muscle and muscle mass, and reduced fatigue, in patients with cirrhosis, researchers report in the November issue of Clinical Gastroenterology and Hepatology.

Cirrhosis is characterized not only by hepatic fibrosis and progressive liver dysfunction, but also reduced exercise tolerance, based on decreased peak exercise uptake of oxygen (peak VO2). Even patients with early-stage cirrhosis have 40% lower peak VO2 values than healthy people.

Reduced exercise tolerance is associated with morbidity and mortality before and after liver transplantation, as well as fatigue, depression, and reduced quality of life.

Laura Zenith et al. performed a pilot study to evaluate the effects of supervised exercise on peak VO2, muscle mass, and quality of life in 19 patients with Child–Pugh class A or B cirrhosis (79% male; average age, 58 years).

The patients were randomly assigned to groups that received exercise training (n = 9) or usual care (controls, n = 10). The exercise group rode a cycle ergometer 3 days/week for 8 weeks at 60%–80% of their baseline peak VO2. At each session, the patients warmed up for 5 minutes with low-level cycling and then cycled for 30 minutes, increasing by 2.5 minutes each week. Each session was followed by a 5-minute cool down.

After the 8-week period, the patients who received the exercise training had peak VO2 values 5.3 mL/kg/min greater than those of controls. They also had significantly greater thigh circumference, thigh muscle thickness, and perceived health status, as well as less fatigue than controls. No adverse events occurred during cardiopulmonary exercise testing or training.

Zenith et al. say that these findings are important because in healthy populations, an increase of 3.5 mL/kg/min has been associated with a 12%–18% increase in survival. Aerobic exercise improves blood flow to skeletal muscles and oxygen extraction by active muscles to increase peak VO2 values.

The increase in muscle thickness observed in the exercise group is important because muscle wasting is an independent predictor of mortality in patients awaiting liver transplants.

Zenith et al state that the study was limited by the small population and the fact that the patients all had early-stage disease. However, they say that the lack of adverse outcomes supports the performance of these larger trials, possibly in patients with more advanced disease.

Only aerobic exercise was evaluated in this study, so it will be interesting to learn whether resistance training, alone or in combination with aerobic training, are safe or more effective for patients with cirrhosis.

Future studies are needed to confirm these findings and determine the mechanisms that impair the aerobic capacity of patients with cirrhosis.

The authors also hope to learn whether exercise affects clinical outcomes, such as retained functional status and reduced mortality.
 Continue reading...

Monday, November 3, 2014

MSF responds to BMS commercial strategy for hepatitis C drug daclatasvir in developing countries

Bristol-Myers' 91-country hep C access plan still draws fire from price critics
November 3, 2014 | By Carly Helfand
Bristol-Myers Squibb ($BMY) is taking Gilead's ($GILD) lead when it comes to developing-world access for its hepatitis C drug, offering up a tiered pricing strategy and licensing agreements with generics makers. But according to some critics, that's not enough.
Continue reading @ FiercePharma

Bristol-Myers Plan to Widen Access to its Hep C Drug, But Meets Criticism
By ED SILVERMAN
A Bristol-Myers spokeswoman would not comment on the criticism or the study, but did send a note saying “our prices in developing countries will take into consideration several factors that include economic development and the burden of disease within a country, as well as the commitment of the government to holistically address hepatitis C, including treatment and care. We are currently engaged in discussions with several high disease burden developing-countries on their plans to address hepatitis C, and the role that Bristol-Myers Squibb can potentially play.”

BMS
HCV Developing World Strategy
Bristol-Myers Squibb recognizes the significant public health challenge that hepatitis C (HCV) presents worldwide, including the substantial burden of the disease in the developing world. With more than 80% of the global HCV patient population living in low- and middle-income countries, there is great need for hepatitis C treatment options in these countries. The significant challenges facing many of these countries are not homogeneous, in particular the need for governments, non-governmental organizations, civil society and industry to form coalitions.

As part of our Company-wide commitment to increasing access to medicines for patient populations in need, we have initiated discussions with government health authorities and other stakeholders in a number of developing countries to facilitate access to daclatasvir. Bristol-Myers Squibb’s HCV developing world access approach will utilize tiered pricing, licensing agreements and working in collaboration with other stakeholders who share in our commitment to working toward the eradication of hepatitis C.



Our tiered pricing model for daclatasvir will take into consideration several factors, including countries’ economic development and burden of disease, as well as the commitment of the government to holistically address hepatitis C, including treatment and care. The lowest pricing tier will apply to all low-income and least developed countries. In addition, in 90 countries (see list at right), Bristol-Myers Squibb will work with licensed generic manufacturers to supply licensed versions of daclatasvir. We are eager to leverage our considerable experience in developing world access to our HIV medicines in order to bring daclatasvir to the developing world as soon as possible.

MSF responds to BMS commercial strategy for hepatitis C drug daclatasvir in developing countries

Background

Pharmaceutical company Bristol-Myers Squibb (BMS) has recently revealed a restrictive commercial strategy for sales of its new direct-acting antiviral (DAA) hepatitis C drug daclatasvir in developing countries. This new generation of drugs to treat hepatitis C is giving hope to the 185 million people infected with the disease today, as these drugs are expected to improve treatment and provide significantly higher chances of cure.

But the prices of these drugs are of grave cause for concern. Gilead’s sofosbuvir, the first DAA which received USFDA approval, is priced at US$84,000 per three-month treatment course in the United States, and nearly $95,000 per treatment when used in combination with another DAA, ledipasvir. These prices will hinder any attempt to scale up treatment of the disease.

But studies have suggested that the cost to produce these drugs is just a tiny fraction of the price of the drug; sofosbuvir costs just $68 - $136 per treatment to produce. One of these studies, from Liverpool University, suggests daclatasvir could cost as little as $10 - $30 to produce for a 12 week course of treatment. BMS has not yet announced the price for developing countries for daclatasvir, but the company has announced that it will create a tiered pricing strategy for the drug. Tiered pricing is a marketing strategy that sets different prices for different countries, most often based on macroeconomic factors; the effect is that middle-income countries – where nearly three-quarters of the world’s poor, and over 70 percent of people with hepatitis C, live – are required to pay high prices that are unaffordable to treatment providers such as MSF, government health programs, and patients who must pay for medicines out of pocket.

BMS also announced its intention to negotiate voluntary licenses – which allow selected generic manufacturers to market cheaper versions of a drug – but with a geographical coverage of only 90 developing countries. Restrictive licensing terms can prevent generic competition where it is needed most: the BMS policy could mean that many middle-income countries with a significant burden of hepatitis C, including China, Egypt and Ukraine, are excluded from access to more affordable generic versions of daclatasvir and will have to pay higher prices. The ability to produce or import generic versions of daclatasvir will be critical to significantly reduce prices of these drugs, as well as to develop or sell fixed-dose combinations that are expected to provide the best treatment outcomes for patients.

Registration of daclatasvir in all countries will also be key; BMS has indicated that it does not have plans to register the drug worldwide, which will seriously hinder access in those countries where BMS chooses not register the drug.

Finally, BMS has largely decided their plans in secret, sharing very few details on plans for registration, price and access ahead of the announcement, an approach that is reminiscent of industry approaches in the early years of the AIDS epidemic and unacceptable by any standard today. Details shared ahead of the announcement have been purposefully vague and BMS has not yet committed to publishing any licence agreement it signs with generic manufacturers in the future, or its tiered pricing structure for developing countries.

BMS’ secrecy and very restrictive commercial plans for developing countries is of grave concern, given the medical importance of daclatasvir; studies have shown it to have high rates of cure when used in combination with other DAAs. Daclatasvir is also pan-genotypic, showing it is effective for genotype 3, which has proven difficult to treat with other DAAs and is highly prevalent among people living with hepatitis C in India and Pakistan.

Médecins Sans Frontières (MSF) responds to the news of BMS’s plans on access and licencing for daclatasvir:
“Unfortunately, history seems to be repeating itself with BMS, who haven’t learnt from the company’s poor track record responding to the HIV epidemic; it is disappointing that BMS is choosing to lock out millions of people from gaining affordable access to daclatasvir, and will not commit to registering the drug in all countries that have a hepatitis C burden, even those that do not represent a commercial opportunity for BMS.
“Once again, people in middle-income countries – where nearly three-quarters of the world’s poor, and over 70 percent of people with hepatitis C, live – are the ones left empty-handed. Affordable access to daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can.  MSF hopes that excluded governments will take all relevant measures available under global trade rules and national patent laws to secure access to low-cost generic versions of these medicines.
“BMS’ secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to hepatitis C drugs for millions of people across the developing world.”
- Rohit Malpani, Director of Policy and Analysis, Médecins Sans Frontières Access Campaign.

Source

Updated November 3, 2014
Reducing the cost of new hepatitis C drugs
Daclatasvir, Harvoni (ledipasvir/sofosbuvir) and Sovaldi.
An index of articles & research weighing the pros and cons over the high price of hepatitis C drugs.

'Unacceptable' Hepatitis C services leading to 'thousands of unnecessary deaths'

'Unacceptable' Hepatitis C services leading to 'thousands of unnecessary deaths'

"Unacceptable" hepatitis C services in England are leading to thousands of unnecessary deaths, according to new research.

D eaths caused by the blood-borne virus, which affects the liver, have quadrupled since 1996 , the Hepatitis C Coalition said.

It blamed poor service provision and late identification and treatment and warned that deaths from the virus could continue to grow for at least 20 years if left unchecked.

And it called for ministers to commit to halving liver cancers and deaths related to the virus by 2020 and completely eliminate it by 2030.

Professor Mark Thursz, chair of the Hepatitis C Coalition, said: "We are in a very fortunate position to have cost effective treatments that will cure the majority of hepatitis C patients but we need to find these patients and treat them.

"To seize this opportunity we need strong national leadership, co-ordination and oversight to ensure patients do not die prematurely when a cure is available."

Around 160,000 people are chronically infected with hepatitis C in England alone, with an estimated 215,000 chronic patients in the whole of the UK.

Deaths from the virus, which can infect and damage the cells of the liver, rose from 98 in 1996 to 428 in 2012, according to Public Health England (PHE) figures.

It means that deaths from hepatitis C are rising faster than any disease among the UK's list of five "big killers" - heart disease, stroke, cancer, lung and liver disease.

Although there is no vaccine, early treatment can successfully get rid of the virus and ongoing infection can be managed.

Rolling Stones guitarrist Keith Richards, actress Pamela Anderson and singer Marianne Faithfull are among high-profile patients who have been diagnosed with hepatitis C.

The virus is spread through contact with an infected person's blood and if left untreated can cause cirrhosis, liver cancer and death.

An estimated 49% of people who inject drugs in England are thought to have it, but sharing razors or toothbrushes is also a risk.

In most cases, the virus causes no noticeable symptoms until the liver has been significantly damaged but w hen symptoms do occur they can easily be mistaken for other conditions such as flu or depression.

The Hepatitis C Coalition's Vision For Change In Hepatitis C report sets out eight recommendations, including improvements in diagnosing and screening for the virus and quicker access to medicines.

It also called for the Department of Health to take responsibility for a plan to coordinate effective testing, treatment and prevention.

Dr Paul Cosford, medical director at PHE, said: "We welcome initiatives that stimulate discussion around hepatitis C and the challenges we face tackling the infection.

"With around 160,000 people in England living with chronic hepatitis C, there is an urgent need to scale up our response and prevent more deaths and serious illness.

"The landscape of hepatitis C treatment is changing rapidly and an era of vastly improved treatment is potentially on the way, but while disease burden continues to rise we must implement better monitoring and reporting of treatment outcomes, as well as expansion of treatment into non-traditional settings, such as primary care, drug treatment centres, and prisons."

At The Crossroads, Part 2: Finding Hep C Infections Before It's Too Late

A new series from Rhode Island Public Radio
At The Crossroads: The Rise Of Hepatitis C And The Fight To Stop It

That’s what has happened with hepatitis C. This virus slowly attacks the liver. It’s often 20 years or more before someone who’s infected notices anything wrong. Meanwhile, the infection scars the liver. And that could lead to cirrhosis or even liver cancer. Most of the estimated five million Americans who have chronic hepatitis C are somewhere on this spectrum of sickness right now.

Providing medical assistance to low income Rhode Islanders will cost the state more than projected. One of the major factors behind the increase is the cost of two new drugs.                   
Read more

Addiction usually leaves a wake of chaos, and all kinds of casualties - marriages, jobs, health. Most tragically, the current crisis of opioid addiction (to prescription painkillers and heroin) in Rhode Island has cost too many lives. Well over 160 Rhode Islanders have died from accidental opioid overdoses so far this year. Hundreds more might have joined them had it not been for the rescue drug naloxone.
Read more

About the series:
Hepatitis C infects an estimated five million Americans, though most of them don’t know it. But deaths from hepatitis C are on the rise in baby boomers. And throughout New England, new infections are creeping up among a younger generation. Less than a year ago, their only options for treatment were complicated regimens of injections that didn’t always lead to a cure. But brand new drugs could change everything. That is, if the cost doesn’t break us.

Acknowledgments
This series was produced by Kristin Gourlay, and edited by Catherine Welch, as a project for The California Endowment Health Journalism Fellowships, a program of the USC Annenberg School for Communication and Journalism.

Support for health care reporting on Rhode Island Public Radio also comes from the Rhode Island Foundation, Rhode Island's only community foundation.

Jake Harper produced the infographics for "At the Crossroads."

Read more.....

Sunday, November 2, 2014

Weekend Reading: HEPATITIS C–A RISK FACTOR FOR GALLSTONE DISEASE


HEPATITIS C–A RISK FACTOR FOR GALLSTONE DISEASE

Good afternoon folks, its a lovely Sunday here in Michigan, a perfect day for a walk around the neighborhood. Did you all have a great Halloween? Our little people sure did, despite a few snowflakes.

Welcome back to another edition of weekend reading. Today's subject is gallbladder disease and HCV. 

ORIGINAL ARTICLE 
HEPATITIS C–A RISK FACTOR FOR GALLSTONE DISEASE 
Syed Inamullah Shah, Sajida Shah*, Abdul Hannan Department of Surgery, Fauji Foundation Hospital, *Department of Radiology, Combined Military Hospital, Rawalpindi

Download PDF

BACKGROUND: There is increasing evidence that chronic liver disease is one of the risk factors for gallstone disease. A few published studies have documented the link between Hepatitis C Virus (HCV) related chronic liver disease and increased incidence of gallstones but these studies did not exclude subjects with other risk factors like cirrhosis. This study aimed to establish an association between HCV infection and gallstones by excluding subjects with all other risk factors for gallstones.
METHODS: This cross sectional study was carried out at four hospitals of Rawalpindi, Pakistan, over a period of 18 months. It included all cases referred for ultrasound scan of abdomen. A total of 2000 cases, were included in the study by consecutive, non-probability sampling. Anti-HCV antibody test was carried out in all subjects by ELISA and sonography was done to determine presence or absence of gallstones.
RESULTS:Patients suffering from HCV had a significantly high percentage of gallstones as compared to seronegative subjects (p = 0.001). In seropositive group, more males had gallstones (p = < 0.001) and prevalence of gallstones was significantly high in younger population with age at or below 40 years (p = < 0.001).
CONCLUSION: Risk of gallstone disease is increased in patients suffering from HCV infection. This association is more pronounced in males.

INTRODUCTION
HCV is globally distributed and it is estimated that up to 170 million people (3% of the world’s population) are infected worldwide.1 In Pakistan, about 4.7% of the population is HCV positive. This ranks as the second highest percentage after Egypt (15.5%).

In recent years more and more males have been diagnosed with symptomatic gallstones and their complications including choledocholithiasis, gallstone pancreatitis and cholangitis. A significant proportion of these patients have been observed to be seropositive for HCV.

Association of gallstones with chronic liver disease is documented in medical literature1,3,4 but no such study has been carried out in Pakistan or the subcontinent despite the fact that HCV is endemic in this region. Risk factors described for gallstones include hyperlipidemia5 , obesity6,7, high serum levels of female sex hormones8 , sickle cell disease, and thalassaemia9 among others. Cirrhosis of liver is a known risk factor for gallstones10,11 but very little is known about gallstone disease in individuals with HCV infection without cirrhosis. 1,4 None of the studies previously conducted have investigated HCV infection as a solitary risk factor for gallstones. 

Some findings of these studies have a significant bearing on the health economy. It has been found that HCV positive subjects develop gallstone disease at a younger age3 and are more likely to have gallstones in bile ducts (0.4%) as compared to normal population (0.1%). 12 It was also found that males with HCV infection were more likely to need surgery for gallstone disease compared to women.5 Keeping in view that HCV infection is endemic in Pakistan, the demographics of the affected population and the burden on the hospitals for gallstone related complications would lead to a significant financial burden. A common observation was made in our institution that there was a clear difference in gall stones occurrence in patients with and without HCV infection. Our hypothesis was that HCV infection is a risk factor for gallstone disease. 

The objective of this study was to compare the frequency of gallstones in patients who have hepatitis C virus infection, with seronegative subjects.

MATERIAL AND METHODS
This cross-sectional study was carried out from November, 2011 to April, 2013 at the Fauji Foundation Hospital and the Combined Military Hospital at Rawalpindi. Patients from Military Hospital and AlIhsan Hospital were also included. In order to maintain the same standard in sonography, all the scans were performed by the same radiologist.

The study included all cases referred for ultrasound scan of abdomen. Patients in this study were sampled by consecutive nonprobability sampling technique. Data was collected using a structured pro forma. Anti-HCV antibody was tested by ELISA on all subjects. An equal number of patients with and without HCV infection were chosen and presence of any gallstones was observed in both groups. Ultrasound scan of abdomen was done on all subjects and special note was made of gallstones in the gallbladder or the bile ducts and presence or absence of cirrhosis.

Patients diagnosed as suffering from hepatitis C were included in Group-1 while those without Hepatitis C were included in Group-2. Patients of either gender, between and including the ages of 18 years and 70 years, were included. An equal number of HCV positives and HCV negative patients were included without taking into account their gender. Patients who were excluded from study were those with: deranged LFTs due to any cause other than hepatitis C; deranged lipid profile; BMI in obese range; acute or fulminant hepatitis and/or cirrhosis; pregnancy; sickle cell disease; malignancy; thalassemia; and history of abdominal surgery or birth control measures. Anti-HCV antibody detected positive by ELISA at least three months before the ultrasound examination was considered as suffering from HCV infection.

Gallstones were considered present if they were detected on ultrasound. Data was analyzed by SPSS-18. Chi-square test was used to determine the association of HCV infection with gallstones by comparing the frequency of gallstones in the two groups. p-value of <0.05 was considered significant. Odds Ratios with 95% confidence intervals (CI) were also calculated.

RESULTS
A total of 2000 patients were included in the study, 1000 subjects were HCV negative and while the other 1000 subjects were HCV positive. Of the total 2000 participants in the study, 1066 (53.3%) individuals were males while 934 (46.7%) were females. The age of subjects ranged between 19 and 66 years with a mean of 41.66±10.11 years. As far the age groups are concerned, 63.2% of the HCV positive subjects aged 40 years or below, while 60.4% of HCV negative group were above 40 years of age. Males and females with Hepatitis C antibodies were 575 (57.5%) and 425 (42.5%) respectively.

Overall presence of gallstones in both groups was a total of 514 subjects (25.7%). In HCV negative males, gallstones were found in only 0.9% as compared to 13.9% in females. Frequency of gallstones in both groups and their comparison is shown in Table-1.


Gender distribution of gallstones in both groups is detailed in Table-2 whereas Figure-1 shows age distribution. The odds ratio for exposure of HCV and effect of gall stones with 95% confidence interval was 3.39 (95% CI 3.1 to 4.8). The results are statistically significant with a risk range given in the CI for those exposed compared to non-exposed. Distribution of gall stones in either gender showed that frequency of gallstones is high in HCV positive males (p=.001) but decreases in HCV positive females.


FIGURE 1


Quantity of stones in gallbladder was labeled as single, multiple or no stones. Cross tabulation of number of stones with study group revealed a significant association between multiple gallstones and HCV infection (p=<.001) as shown in Table-3


Presence of gallstones in the common bile duct was evaluated between the two groups. There were more cases of CBD gallstones in HCV positive group (2.5%) as compared to HCV negative group (0.9%). The difference is statistically significant (p=<0.001).

DISCUSSION 
Cholelithiasis has been traditionally associated with middle aged females. Gall stones are of various types but the commonly found calculi are cholesterol stones. Risk factors described for cholesterol stones, in addition to those described above, include rapid weight loss13,14 female sex hormones8,15,16, multiparity and diabetes mellitus.

Cirrhosis has long been known to be a risk factor for gallstones.10,11,18 Stroffolini et al, reported in 2007 that gallstone prevalence was significantly higher in patients with HCV-related cirrhosis than in those with HBV-related or alcoholic cirrhosis.18 Formation of gallstones in cirrhosis is due to many factors such as reduced secretion of bile acids, reduced gallbladder motility19 and reduced synthesis of cholesterol. Although high estrogen levels have been suggested as a possible mechanism of increased gallstone formation in cirrhotic patients, Li et al did not find any significant differences in plasma levels of sex hormones between cirrhotic with and without gallstones.20

In contrast to the abundance of literature on cirrhosis and its association with gallstones, very little is known about gallbladder disease in individuals with HCV infection in the absence of cirrhosis.

There are only three published studies on this subject so far.1,3,4 Probably the first study to establish the link between HCV infection and gallstone disease was carried out in 2000 at Taiwan. In this study by Chang et al3 , the prevalence of gallstones in HCV positive subjects was found to be significantly higher (11.7%) than the control subjects (6%). Bini et al4 examined the data of more than 13000 subjects who participated in a United States national survey for health and nutrition, in 2005, and discovered that 12.5% of those with HCV infection had gallstone disease, most of whom were males. They also discovered that the relative odds of gallstone disease among persons with HCV infection increased with the severity of liver disease as assessed by serum total bilirubin levels, serum albumin levels, and platelet counts. This was construed as demonstrating a direct link between liver disease and gallstone formation.  A 2009 Romanian study by Acalovschi et al1 , reported 19% incidence of gallstones in HCV positive patients. In our study, we found that a total of 37.4% of HCV positive individuals had gallstones as compared to 14% in HCV negative group.

The significant difference between the two groups (p=.001) clearly establishes an association between HCV infection and gallstone disease, keeping in view the fact that we excluded subjects with all other known risk factors for gallstone disease. As compared to previous studies, the prevalence in this study is higher in both groups. It may be argued that this extraordinarily high prevalence in our results is due to the peculiar sampling technique, but the study of Acalovschi et al used a similar technique with comparable sample size and revealed lower overall prevalence.

Therefore, results of our study may partly reflect an actual rise in the incidence of gallstone disease in Pakistani population.

Bini et al found that HCV infection was a strong risk factor for gallstone disease in men but not in women. 4 The reason for this difference is not cited except for the likelihood that the pathophysiology of and risk factors for gallstone formation differ among men and women. This study corroborates this observation as our results that show that 28.2% of HCV positive males had gallstone disease whereas prevalence in HCV positive females was only 8.5%. This difference becomes more significant because only 0.1% HCV negative males in our study had gallstone disease whereas 19.2% HCV negative females had the disease. This means that HCV infection may actually be protective to women against gallstone disease. In contrast, males revealed a strong association (p=.001) between HCV infection and gallstones.

Our results revealed that younger males are more prone to acquire gallstones if they are HCV positive. This age association is statistically significant in males (p=<.001). These results are in conformity with those of Acalovschi et al and Chang et al. 1,3 Younger age group was also found to have a predilection for acquiring multiple gallstones.

There is also a significant association (p=<.001) between HCV infection and development of multiple, as opposed to single gallstones. HCV infection appears to make the patients more prone to suffer from choledocholithiasis.

Various reasons have been postulated for HCV infection causing gallstones. Sluggish function of the liver in synthesizing bile acids has been cited. 21 Direct infection of the gallbladder by HCV22 and gallbladder hypomotility19 has been demonstrated. This direct effect is more probable because an infection by Hepatitis B virus does not increase the risk of gallstone disease4 despite having a similar effect on liver function. Some studies have even suggested a protective effect of hepatitis B in developing gallstones. 23 This direct effect seems to spare the gallbladders in females.

The findings of this study significantly bear on the health economy. As established, males less than 40 years are more prone to develop gallstones if they are HCV positive. These stones are usually multiple with more likelihood of causing obstructive jaundice. These patients are more likely to need surgery for gall stone disease4 and morbidity may be high because of compromised liver function. In economic terms, the breadwinner of the family is disabled, workplace gets affected and hospitals have to allocate more resources for HCV positive patients undergoing surgery.

The strength of our study is in the fact that this is the first attempt to describe association of gallstones with HCV not only in Pakistan but in the entire South Asian region. Secondly, we have been scrupulous in the selection of subjects by excluding those HCV positive individuals who had any other risk factor of gallstone disease. The limitation of this study is that the study sample is not representative of the general population. Subjects were selected from patients coming for treatment to four large hospitals of Rawalpindi.

CONCLUSION 
There is a strong association between HCV infection and gallstones. HCV infection is definitely a risk factor for gallstone disease particularly in young males. By invalidating young subjects and rendering them as potential candidates for surgery, this association has a profound effect on health economy. There is a predilection for HCV positive patients to acquire multiple gallstones. Further studies are needed to evaluate the precise cause for this association.

REFERENCES